Form 4: NovoCure Director Sells Shares to Cover Tax Obligations Following RSU Vesting

NovoCure Ltd. Director Gabriel Leung reported the sale of 999 ordinary shares valued at a weighted average price of $17.3146 per share, a transaction explicitly stated as non-discretionary and solely for tax withholding purposes related to Restricted Stock Unit vesting.

Summary

• Gabriel Leung, a Director of NovoCure Ltd. (NVCR), reported a transaction involving the company's ordinary shares.
• On June 3, 2025, Mr. Leung disposed of 999 ordinary shares.
• The shares were sold at a weighted average price of $17.3146 per share, with individual trades ranging from $17.1025 to $17.50.
• This sale was not a discretionary trade but was mandated by the issuer's award agreement to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Gabriel Leung beneficially owns 81,229 ordinary shares.
• The total beneficial ownership amount was amended to correct a prior mathematical error.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax purposes, which is non-discretionary and does not reflect a change in the director's sentiment or outlook on the company. Therefore, the sentiment is neutral.

Positives

• The transaction was a "sell to cover" for tax withholding, indicating it was not a discretionary sale based on a change in the director's outlook on the company, which is a routine event for RSU vesting.

Negatives

• No inherent negatives as the sale was non-discretionary and for tax purposes.

Risks

• No new risks are introduced by this routine compliance transaction.

Future Outlook

This SEC Form 4 filing pertains to an insider transaction for tax purposes and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
• This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
• Amended total to correct prior mathematical error.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitive dynamics within the oncology or medical device sectors where NovoCure operates.

Comparison to Industry Standards

• This document reports a standard 'sell to cover' transaction for tax purposes, which is a common practice across publicly traded companies when Restricted Stock Units (RSUs) vest for executives and directors. It does not contain financial or operational results that can be compared to industry benchmarks or specific competitor performance.

Stakeholder Impact

• Shareholders: The sale of a small number of shares for tax purposes by a director is a routine event and is unlikely to have a material impact on the company's stock price or shareholder value.
• Employees: The transaction relates to the vesting of Restricted Stock Units, which is part of standard employee equity compensation plans, indicating the ongoing operation of such plans.

Next Steps

• The document does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the completion of this transaction.

Key Dates

Keywords

NovoCure, NVCR, Form 4, insider transaction, share sale, director, beneficial ownership, restricted stock units, RSU, tax withholding, corporate governance